PEDIATRICS Vol. 119 No. 4 April 2007, pp. 684-697 (doi:10.1542/10.1542/peds.2006-2876)
ARTICLE |
Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States
a Viral Gastroenteritis Team, Respiratory and Enteric Viruses Branch
b Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
OBJECTIVE. In February 2006, a safe, efficacious, orally administered pentavalent human-bovine reassortant rotavirus vaccine was licensed and recommended for routine immunization of all children in the United States. We assessed the health and economic impacts of a national rotavirus immunization program in the United States.
METHODS. Monte Carlo cost-effectiveness analyses, from health care and societal perspectives, of vaccination of a hypothetical US birth cohort of 4010000 children monitored from birth to 59 months of age were performed. We compared the disease and economic burden of rotavirus infection in an unvaccinated cohort of children with one vaccinated at 2, 4, and 6 months with pentavalent human-bovine reassortant rotavirus vaccine.
RESULTS. A routine rotavirus immunization program would prevent 13 deaths, 44000 hospitalizations, 137000 emergency department visits, 256000 office visits, and 1100000 episodes requiring only home care for children <5 years of age in the United States. Assuming costs of administration of $10, the break-even price per dose of vaccine was $42 from the societal perspective and $12 from the health care perspective. From the societal perspective, at the manufacturer's price of $62.50 per dose, vaccination would cost $138 per case averted, $3024 per serious case averted, and $197190 per life-year saved, at a total cost of $515 million to the health care system and $216 million to society. Key variables influencing the results were parental workdays lost, costs of hospitalization, emergency department visits, and child care.
CONCLUSIONS. Despite a higher burden of serious rotavirus disease than estimated previously, routine rotavirus vaccination would unlikely be cost-saving in the United States at present. Nonetheless, rotavirus vaccination may still be considered a cost-effective intervention.
Key Words: rotavirus vaccines • cost-benefit analysis • United States
Abbreviations: PRV—pentavalent human-bovine reassortant rotavirus vaccine • RRV-TV—tetravalent rhesus-human reassortant rotavirus vaccine • ICD-9-CM—International Classification of Diseases, Ninth Revision, Clinical Modification • DTaP—diphtheria-tetanus-acellular pertussis • CDC—Centers for Disease Control and Prevention
Accepted Dec 12, 2006.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Desselberger, E. Manktelow, W. Li, W. Cheung, M. Iturriza-Gomara, and J. Gray Rotaviruses and rotavirus vaccines Br. Med. Bull., June 1, 2009; 90(1): 37 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chodick, O. Waisbourd-Zinman, V. Shalev, E. Kokia, M. Rabinovich, and S. Ashkenazi Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel Eur J Public Health, June 1, 2009; 19(3): 254 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Committee on Infectious Diseases Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine Pediatrics, May 1, 2009; 123(5): 1412 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Tate, A. T. Curns, M. M. Cortese, E. S. Weintraub, S. Hambidge, K. M. Zangwill, M. M. Patel, J. M. Baggs, and U. D. Parashar Burden of Acute Gastroenteritis Hospitalizations and Emergency Department Visits in US Children That Is Potentially Preventable by Rotavirus Vaccination: A Probe Study Using the Now-Withdrawn RotaShield Vaccine Pediatrics, March 1, 2009; 123(3): 744 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bilcke, P. Van Damme, and P. Beutels Cost-Effectiveness of Rotavirus Vaccination: Exploring Caregiver(s) and ``No Medical Care'' Disease Impact in Belgium Med Decis Making, January 1, 2009; 29(1): 33 - 50. [Abstract] [PDF]
|
|
|
|
|
|
D. C. Payne, M. A. Staat, K. M. Edwards, P. G. Szilagyi, J. R. Gentsch, L. J. Stockman, A. T. Curns, M. Griffin, G. A. Weinberg, C. B. Hall, et al. Active, Population-Based Surveillance for Severe Rotavirus Gastroenteritis in Children in the United States Pediatrics, December 1, 2008; 122(6): 1235 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Yee, M. A. Staat, P. Azimi, D. I. Bernstein, R. L. Ward, C. Schubert, D. O. Matson, R. M. Turcios-Ruiz, U. Parashar, M.-A. Widdowson, et al. Burden of Rotavirus Disease Among Children Visiting Pediatric Emergency Departments in Cincinnati, Ohio, and Oakland, California, in 1999-2000 Pediatrics, November 1, 2008; 122(5): 971 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pfoh, M. R. Wessels, D. Goldmann, and G. M. Lee Burden and Economic Cost of Group A Streptococcal Pharyngitis Pediatrics, February 1, 2008; 121(2): 229 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P Buttery Routine rotavirus vaccinations of infants cost US$138 per case averted and US$197 190 per life year saved from a societal perspective Evid. Based Med., October 1, 2007; 12(5): 153 - 153. [Full Text] [PDF]
|
|
